Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cellectis S.A.
Age
12–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have measurable or evaluable disease in the bone marrow (BM) of at least 5% blasts at the time of enrollment
Received prior autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (unless participants were not able to receive prior autologous anti-CD19 CAR T-cell therapy or if autologous anti-CD19 CAR T-cell therapy has not been available due to any reason or documented as CD19 negative relapsed or refractory B-ALL.
Cohort A:
\- At least 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
Cohort B:
\- Less than 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
You may not be if
Prior CD22 CAR-T cell therapy
More than 1 allogenic hematopoietic stem cell transplant (HSCT)
Active, acute, or chronic graft-versus-host disease (GvHD)
White blood cell (WBC) count ≥ 50,000 cells/μL at Screening or rapidly progressive disease (PD) that, in the estimation of the Investigators and Sponsor, would compromise ability to complete study therapy
Radiologically detected central nervous system (CNS) leukemia or CNS-3 disease
